|

Sirolimus Clinical Trials

21 actively recruiting trials across 12 locations

▲ +2 trials since August 2026

Also known as: AY 22989, AY-22989, AY22989, RAPA, RAPAMYCIN +10 more

Pipeline

Phase 1: 3Phase 2: 7Phase 4: 2Phase 1/2: 6Phase 2/3: 2

Top Sponsors

  • National Cancer Institute (NCI)5
  • Fred Hutchinson Cancer Center2
  • City of Hope Medical Center2
  • University of Nebraska1
  • University of Michigan Rogel Cancer Center1

Indications

  • Cancer19
  • Hematologic Neoplasms3
  • Myelodysplastic Syndrome3
  • Acute Myeloid Leukemia3
  • Acute Lymphoblastic Leukemia3

Other4 trials

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Phase 2/3
Methods of T Cell Depletion Trial (MoTD)
Phase 2
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Phase 2/3
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Phase 4

Duarte, California3 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

City of Hope

Phase 1/2
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

City of Hope Medical Center

Phase 2

Bethesda, Maryland3 trials

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center

Phase 1
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2

Tampa, Florida2 trials

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

Moffitt Cancer Center

Phase 1/2
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Moffitt Cancer Center

Phase 2

Birmingham, Alabama1 trial

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

University of Alabama at Birmingham

Phase 2

La Jolla, California1 trial

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

UC San Diego Moores Cancer Center

Phase 1/2

Stanford, California1 trial

Safety and Durability of Sirolimus for Treatment of LAM

Stanford University Medical Center

Atlanta, Georgia1 trial

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Aflac Cancer & Blood Disorders Centers

Phase 2

Iowa City, Iowa1 trial

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

University of Iowa Health Care

Phase 1

Boston, Massachusetts1 trial

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Brigham and Women's Hospital

Phase 4

Ann Arbor, Michigan1 trial

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

University of Michigan Cancer Center

Phase 2

Omaha, Nebraska1 trial

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

University of Nebraska Medical Center

Phase 2

Seattle, Washington1 trial

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.